Business
Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units
CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical S.A., the product’s exclusive distributor in Greece. Under the terms of the agreement, Cosm
About this update from Cosmos Health Inc.
[{"type":"image","alt":"Cosmos Health Inc.","displaySize":"","headline":null,"caption":"Cosmos Health Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/340010e4b2fe348130647e37170a6c2a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zU4V54zW1TjV8qFkho7Qmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/340010e4b2fe348130647e37170a6c2a","width":300,"height":157}},"lazy":false},{"type":"text","content":"CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical S.A., the product’s exclusive distributor in Greece.","length":476,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and product release, in accordance with applicable regulatory requirements.","length":266,"tagName":"p"},{"type":"text","content":"PathMuscle is an advanced generic pharmaceutical product formulated as a fixed-dose combination of thiocolchicoside, a centrally acting muscle relaxant, and paracetamol (acetaminophen), an analgesic and antipyretic agent. The combination is designed to address musculoskeletal conditions by providing both muscle-relaxant activity and pain relief within a single dosage form.","length":375,"tagName":"p"},{"type":"text","content":"PathMuscle is approved in multiple oral presentations, including film-coated tablets containing thiocolchicoside 2 mg and paracetamol 500 mg, supplied in 30-tablet Alu/PVC blister packs, as well as soluble tablets containing thiocolchicoside 4 mg and paracetamol 1,000 mg, supplied in 20-tablet Alu/PVC blister packs, and is indicated for the symptomatic treatment of painful muscle spasms associated with acute musculoskeletal disorders.","length":438,"tagName":"p"},{"type":"text","content":"The product will be distributed and commercially promoted in th...